HIV-Druginteractions.org

Cookies policy. You will see this message only once.
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that
you’re happy to receive all cookies on this site. However, if you would like to, you can change your cookie settings at any time. Find out more.

Papers

Papers arising from work carried out by the group are listed below. Please note that preliminary data may have been presented at meetings prior to publication of the final analysis. For papers published from 2002 onwards, a link to the PubMed abstract is provided if available.

We would like to take this opportunity to thank all those who have participated in the various studies: their role is of great importance and does not always get the recognition it deserves.

Entries for the current year and three preceding years are shown here. Older entries can be found in the archive.

2013

2012

2011

2010

Archive

2013

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M. J Acquir Immune Defic Syndr, 2013, 62(3): 275-281.

Correlates of efavirenz exposure in chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.
Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, Porte CJ. Ther Drug Monit, 2013, 35(1): 78-83.

Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.
Seden K, Khoo SH, Back D, Byakika-Kibwika P, Lamorde M, Ryan M, Merry C. J Antimicrob Chemother, 2013, 68(1): 1-3.

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G. J Acquir Immune Defic Syndr, 2013, ;62(1): 60-6.

2012

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.
Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D. Clin Pharmacol Ther, 2012, 92(4): 494-502.

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.
Olagunju A, Owen A, Cressey TR. Pharmacogenomics, 2012, 13(13): 1501-22.

Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
Yilmaz A, Watson V, Dickinson L, Back D. Antimicrob Agents Chemother, 2012, 56(9): 4583-5.

Divalent metals and pH alter raltegravir disposition in vitro.
Moss DM, Siccardi M, Murphy M, Piperakis MM, Khoo SH, Back DJ, Owen A. Antimicrob Agents Chemother, 2012, 56(6): 3020-3026

Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Schipani A, Egan D, Dickinson L, Davies G, Boffito M, Youle M, Khoo SH, Back DJ, Owen A. Antivir Ther, 2012, 17(5): 861-8.

Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Siccardi M, DʼAvolio A, Rodriguez-Novoa S, Cuenca L, Simiele M, Baietto L, Calcagno A, Moss D, Bonora S, Soriano V, Back DJ, Owen A, Di Perri G. Ther Drug Monit, 2012, 34(2): 232-235.

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.
Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M. Antimicrob Agents Chemother, 2012, 56(3):1 427-433.

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. Antimicrob Agents Chemother, 2012, 56(2): 816-824.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.
Liptrott NJ, Pushpakom S, Wyen C, Fätkenheuer G, Hoffmann C, Mauss S, Knechten H, Brockmeyer NH, Hopper-Borge E, Siccardi M, Back DJ, Khoo SH, Pirmohamed M, Owen A; German Competence Network for HIV/AIDS. Pharmacogenet Genomics, 2012, 22(1): 10-9.

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A. J Antimicrob Chemother, 2012, 67(1): 206-12.

2011

IFN-[gamma] 874A>T genotype is associated with higher CCR5 expression in peripheral blood mononuclear cells from HIV+ patients.
Liptrott NJ, Egan D, Back DJ, Owen A. JAIDS, 2011, 58(5): 442–445.

Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Jackson A, Watson V, Back D, Khoo S, Liptrott N, Egan D, Gedela K, Higgs C, Abbas R, Gazzard B, Boffito M. J Acquir Immune Defic Syndr, 2011, 58(5): 450-7.

Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
Hill A, Khoo S, Boffito M, Back D. JAIDS, 2011, 58(5): e137–e138

Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Boffito M, Jackson A, Amara A, Back D, Khoo S, Higgs C, Seymour N, Gazzard B, Moyle G. Antimicrob Agents Chemother, 2011, 55(9): 4218-4223.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back D, Owen A. J Antimicrob Chemother, 2011, 66(9): 2092-2098.

Ageing with HIV: medication use and risk for potential drug-drug interactions.
Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L; on behalf of the Swiss HIV Cohort Study. J Antimicrob Chemother, 2011, 66(9): 2107-2111.

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Else LJ, Taylor S, Back DJ, Khoo SH. Antivir Ther. 2011;16(8):1139-47.

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
Else LJ, Taylor S, Back DJ, Khoo SH. Antivir Ther, 2011, 16(8): 1149-67.

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Bonora S, Di Perri G, Back DJ, Khoo S, Pirmohamed M, Owen A. J Infect Dis, 2011, 204(1): 145-153.

Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.
Dickinson L, Boffito M, Back D, Else L, von Hentig N, Davies G, Khoo S, Pozniak A, Moyle G, Aarons L. Antimicrob Agents Chemother, 2011, 55(6): 2775-2782.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; on behalf of the German Competence Network for HIV/AIDS. J Antimicrob Chemother, 2011, 66(6): 1332-1339.

Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.
Ashby J, Garvey L, Erlwein OW, Lamba H, Weston R, Legg K, Latch N, McClure MO, Dickinson L, D'Avolio A, Back D, Winston A. J Antimicrob Chemother, 2011, 66(6): 1340-1345.

Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
Jackson A, D'Avolio A, Watson V, Bonora S, Back D, Taylor J, Armenis K, Gazzard B, Moyle G, Boffito M. J Antimicrob Chemother, 2011, 66(4): 885-9.

Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.
Else LJ, Lyons F, O'Shea S, Costello S, Mullen J, Lechelt M, Dickinson L, Magaya V, Back DJ, de Ruiter A. AIDS, 2011, 25(5): 722-5.

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
Jackson A, Hill A, Puls R, Else L, Amin J, Back D, Lin E, Khoo S, Emery S, Morley R, Gazzard B, Boffito M. J Antimicrob Chemother, 2011, 66(3): 635-40.

The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?
Liptrott NJ, Owen A. Expert Opin Drug Metab Toxicol, 2011, 7(3): 341-352.

Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.
Kigen G, Kimaiyo S, Nyandiko W, Faragher B, Sang E, Jakait B, Owen A, Back D, Gibbons S, Seden K, Khoo SH; on behalf of the USAID-Academic Model for Prevention Treatment of HIV/AIDS. PLoS One, 2011, 6(2): e16800.

Adipogenic gene variants in patients with HIV-associated lipodystrophy.
Pushpakom SP, Owen A, Vilar FJ, Castro H, Dunn DT, Back DJ, Pirmohamed M. Pharmacogenet Genomics, 2011, 21(2): 76-83.

Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.
Caswell RJ, Phillips D, Chaponda M, Khoo SH, Taylor GP, Ghanem M, Poulton M, Welch J, Gibbons S, Jackson V, Lambert JS. Int J STD AIDS, 2011, 22(1): 11-14.

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Lambert J, Else L, Jackson V, Breiden J, Gibbons S, Dickinson L, Back D, Brennan M, Connor E, Boyle N, Fleming C, Coulter-Smith S, Khoo S. HIV Med, 2011, 12(3): 166-173.

Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir.
Moss DM, Kwan WS, Liptrott NJ, Smith DL, Siccardi M, Khoo SH, Back DJ, Owen A. Antimicrob Agents Chemother, 2011, 55 (2): 879-887.

Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients.
Moltó J, Valle M, Back D, Cedeño S, Watson V, Liptrott N, Egan D, Miranda C, Barbanoj MJ, Clotet B. Antimicrob Agents Chemother, 2011, 55(1): 72-75.

Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Ryan M, Coakley P, Boffito M, Namakula R, Kalemeera F, Colebunders R, Back D, Khoo S, Merry C. J Antimicrob Chemother, 2011, 66(1): 180-183.

Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Moltó J, Valle M, Back D, Cedeño S, Watson V, Liptrott N, Egan D, Miranda C, Barbanoj MJ, Clotet B. Antimicrob Agents Chemother, 2011, 55(1): 72-5.

2010

Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Pharmacogenet Genomics, 2010, 20(12): 759-65.

Grapefruit-drug interactions.
Seden K, Dickinson L, Khoo S, Back D. Drugs, 2010, 70(18): 2373-2407.

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, Svennerholm B, Gisslén M. J Acquir Immune Defic Syndr, 2010, 55(5): 590-6.

Pharmacokinetic evaluation of etravirine.
Dickinson L, Khoo S, Back D. Expert Opin Drug Metab Toxicol, 2010, 6(12): 1575-85.

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Rodríguez Novoa S, Cuenca L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod HL, Davies G, Khoo S, Back DJ, Di Perri G, Owen A. Antimicrob Agents Chemother, 2010, 54(12): 5242-50.

Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Randell PA, Jackson AG, Boffito M, Back DJ, Tjia JF, Taylor J, Mandalia S, Moyle GJ. Antivir Ther, 2010, 15(8): 1125-32.

Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Flaherty JP, Boffito M, Namakula R, Ryan M, Nakabiito C, Back DJ, Khoo S, Merry C, Scarsi KK. J Acquir Immune Defic Syndr, 2010, 55(3): 345-50.

Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men.
Taylor S, Jayasuriya AN, Berry A, Gilleran G, Dufty NE, Else L, Back DJ, Smit EJ. AIDS, 2010, 24(16): 2583-7.

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A, Vernazza P, Khoo S, Ledergerber B, Back D, Battegay M; Swiss HIV Cohort Study. Antivir Ther, 2010, 15(3): 413-23.

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
Else L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S, Back D. J Chromatogr B Analyt Technol Biomed Life Sci, 2010, 878(19): 1455-65.

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Seden K, Back D, Khoo S. J Antimicrob Chemother, 2010, 65(6): 1079-85.

Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, Carey PB, Khoo SH. Clin Infect Dis, 2010,50(10): 1419-21.

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.
Janneh O, Bray PG, Jones E, Wyen C, Chiba P, Back DJ, Khoo SH. J Antimicrob Chemother. 2010;65(5):906-16.

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A. Antivir Ther. 2010;15(2):213-8.

Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
Wakeham K, Parkes-Ratanshi R, Watson V, Ggayi AB, Khoo S, Lalloo DG. J Antimicrob Chemother, 2010, 65(2): 316-319.

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A. Pharmacogenet Genomics, 2010, 20(2): 112-120.

Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells.
Martin P, Riley R, Thompson P, Williams D, Back D, Owen A. Acta Pharmacol Sin, 2010, 31(1): 51-65.

Pharmacokinetics and drug-drug interactions of antiretrovirals: An update.
Dickinson L, Khoo S, Back D. Antiviral Research, 2010, 85 (1): 176-189.

Factors influencing lopinavir and atazanavir plasma concentration.
Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; UK CHIC Steering Committee. J Antimicrob Chemother, 2010, 65(1): 129-137.

The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.
Janneh O, Owen A, Bray PG, Back DJ, Pirmohamed M. Br J Pharmacol. 2010;159(2):484-93.